About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Multiple Sclerosis Clinical Trials in Phoenix | 142 Studies

Clinical Trials Multiple SclerosisPhoenix

Multiple Sclerosis Clinical Trials in Phoenix

Find 142 clinical trials for multiple sclerosis near Phoenix, Arizona. Connect with research centers in your area.

All Multiple Sclerosis trials nationwide All trials in Phoenix

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 81-100 of 142 trials

CompletedStudy of Electrical Impedance Myography (EIM) in ALSThis trial is studying Electrical Impedance Myography (EIM) for measuring muscle health.NCT02011204·Phoenix, Arizona and 5 others Active not recruitingEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)NCT05147220·Phoenix, Arizona and 199 others

Multiple Sclerosis Trials in Other Cities

New York Los Angeles Chicago Houston Philadelphia San Antonio

Data from ClinicalTrials.govTerms

TerminatedAtacicept in Multiple Sclerosis Extension Study, Phase IIThis study (28851) is a long-term follow-up study of subjects enrolled in ATAMS study 28063 (NCT00642902).NCT00853762·Phoenix, Arizona and 46 others

CompletedComparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study TwoThe purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis…NCT00548405·Cullman, Alabama and 190 others

RecruitingNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisThis is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment.NCT07325292·Cullman, Alabama and 39 others

TerminatedTecfidera Slow-Titration StudyThe primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF…NCT02428231·Gilbert, Arizona and 19 others

CompletedCharacterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)The primary objective of this study is to determine the proportion of participants with relapsing multiple sclerosis who experience new and/or increased flu-like symptoms (FLS)…NCT01939002·Gilbert, Arizona and 37 others

CompletedUsing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsPrimary Objective: To describe efficacy, tolerability and convenience of teriflunomide treatment through the evaluation of Participant Reported Outcomes (PROs).NCT01895335·Birmingham, Alabama and 168 others

CompletedRebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisThe primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects…NCT00078338·Birmingham, Alabama and 79 others

Active not recruitingA Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion…NCT04548999·Homewood, Alabama and 146 others

CompletedEfficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisThe primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple…NCT00906399·Phoenix, Arizona and 177 others

CompletedDimethyl Fumarate (DMF) Observational StudyThe primary objective of the study is to determine the incidence, type, and pattern of serious adverse events (SAEs), including but not limited to infections (including…NCT02047097·Birmingham, Alabama and 467 others

CompletedA Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple SclerosisThis is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.NCT00097188·Phoenix, Arizona and 30 others

CompletedSafety and Tolerability of Glatiramer AcetateThis is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week…NCT01874145·Cullman, Alabama and 34 others

CompletedSafety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying TherapiesThe purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another…NCT01442194·Birmingham, Alabama and 237 others

TerminatedA Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple SclerosisThis is a Phase 3b, multicenter, international study conducted in 2 parts.NCT01416181·Phoenix, Arizona and 160 others

CompletedClinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple SclerosisThis study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple…NCT01093326·Phoenix, Arizona and 70 others

CompletedEvaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy.NCT01623596·Cullman, Alabama and 122 others

CompletedA Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.NCT00882999·Phoenix, Arizona and 62 others

Active not recruitingLong-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MSThe purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab…NCT03650114·Birmingham, Alabama and 294 others

PreviousPage 5 of 8Next

Other Conditions in Phoenix

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia